In most studies and human clinical trials, IL-6 is only mildly elevated [62,63] compared to the high IL-6 levels seen with CAR-T cells in vivo [50], which explains the low rate of cytokine release syndrome (CRS) adverse events caused by CAR-NK cells [50]. The gene discussed is IL6; the disease is congenital rubella syndrome.